Meta-analysis of the prognostic significance of ASXL1 mutation in AML patients with intermediate-risk cytogenetic versus intermediate-risk cytogenetic + NPM1 mutation for Overall survival (OS). The gene discussed is ASXL1; the disease is acute myeloid leukemia.